NCNA - NuCana PLC logo

NCNA

NuCana PLC

Rev —top 1%5Y
Hold

NuCana PLC develops cancer treatments using its ProTide technology to enhance chemotherapy and nucleoside analogs. Its drug pipeline includes NUC-3373 for colorectal cancer and NUC-7738 for advanced solid tumors, currently in various clinical trials.

⚕️ Healthcare NASDAQ Listed 2017 £ GBP
$1,000 invested 5 years ago $0today

Score Overview

1 Year
Score
Net Growth-51.13%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth6.43%
Net Trend60%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-24.37%
Net Trend50%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency

See the full market ranking →

NuCana PLC fundamental performance

Across NuCana PLC's full reported history, from 2017 to 2025, revenue declined from £ 283K to £ 0.00 and net income went from -£ 23M to -£ 28M. Revenue increased in 0% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.43
1 Year2025-08-12
$ 4.71-69.64%
5 Years2021-08-12
$ 10.75K-99.99%
All Time2017-09-28
$ 80.75K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025£ 0.00-£ 28M£ 24M
2024£ 0.00-£ 18M£ 6M
2023£ 0.00-£ 27M£ 17M
2022£ 0.00-£ 32M£ 41M
2021£ 0.00-£ 40M£ 60M
2020£ 0.00-£ 30M£ 87M
2019£ 0.00-£ 21M£ 51M
2018£ 0.00-£ 13M£ 76M
IPO2017£ 283K-£ 23M£ 86M

Explore beyond NCNA

You're looking at NuCana PLC. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies